Aug. 26 at 1:02 PM
$CELZ
~3/31/26 CELZ had 3,696,668 shares outstanding.
In March, CELZ said existing cash was expected to cover anticipated operating costs and capital expenditures “through at least March 2027.”
On June 22, CELZ said the expanded ADAPT cohort could be completed using “existing resources.”
Then came the June 30 warrant deal: 2.79M warrants repriced from
$2.86 to
$1.60, plus 5.58M new
$1.60 warrants.
Afterward, management said CELZ was not compelled to pursue dilution simply to “keep the lights on.”
8/7/26 CELZ had 6,592,557 shares outstanding.
That is a ~78% increase in the share count in about four months.
And now shareholders are being asked to authorize 75M additional shares, despite management identifying no current commitment requiring them.
@CreativeMedical_IR Why would so many shares be needed if CELZ plans to "maintain disciplined capital allocation" through P3.
